NCT05355948Completed
A Clinical Trial to Evaluate the Detection of Atrial Fibrillation for an One Day Versus More Than or Equal to Eight Days Using MEMO Patch PLUS in Individuals Aged ≥ 75 Years, or Those at High Risk of Stroke
A Prospective, Multi-Center, Randomized Clinical Trial to Evaluate the Detection of Atrial Fibrillation for an One Day Versus More Than or Equal to Eight Days Using MEMO Patch PLUS in Individuals Aged ≥ 75 Years, or Those at High Risk of Stroke: MEMO-DAF8
Source: ClinicalTrials.gov · Last updated 1 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate the benefits in the atrial fibrillation detection rate of the continuous ECG monitoring group for more than 8 days by contrasting with one-day ECG monitoring using MEMO Patch PLUS in 1000 patients with atrial fibrillation-related symptoms in the high risk group of stroke. The participant is allocated randomly to One-day ECG monitoring group or the continuous ECG monitoring group for more than 8 days in ratio of 1:1, only if the participant provides informed consent and eligible for all the inclusion/exclusion criteria. The investigator confirms the results of MEMO Patch PLUS monitoring at 1 month from the date of MEMO Patch PLUS attachment. The participation of the subject is terminated on the 1 year from the date of MEMO Patch PLUS attachment. On that day, investigator evaluates incidence of the event associated with atrial fibrillation, the event is included ischemic stroke/transient ischemic accident, hemorrhagic stroke, systemic embolism, etc.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 1000 (actual)
- First submitted
- 21 Apr 2022
- Start date
- 9 May 2022
- Primary completion date
- 31 Jul 2023
- Lead sponsor
- Yonsei University
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT05355948
What you commit to
- Study type: Interventional
- Participants enrolled: 1000
- From 9 May 2022 to the primary completion date, 31 Jul 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- \[Inclusion criteria\]
- A participant will be eligible for inclusion in the study if the participant:
- Has provided documented informed consent for the study.
- Is adult at least 19 years of age on the day of providing documented informed consent
- Is the high risk group for stroke, i.e. adult at least 75 years of age or CHA2DS2-VASc score more than 2
- Is life expectancy more than 6 months
- Has no Atrial fibrillation or Atrial flutter as a result of 12-lead ECG
- Has symptoms associated with Atrial fibrillation \*symptoms associated with Atrial fibrillation: palpitation, dizziness, dyspnea, syncope, stroke/transient ischemic accident, systemic embolism etc.
- \[Exclusion criteria\]
- The participant must be excluded from the study if the participant:
- Has had prior history of Atrial fibrillation or Atrial flutter
- Has inserted Pacemaker or Defibrillator that can diagnose Atrial fibrillation or Atrial flutter
- Has plan of Carotid endarterectomy or inserting Stent\* within 90 days on the day of providing document informed consent \*Stent insertion: means when stent-related interventions have been performed on the carotid arteyr or coronary arteries.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yonsei University Health System, Severance Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
Related publications
- Wearable device derived electrocardiographic age and its association with atrial fibrillation.NPJ Digit Med · 2026 · PMID 41548032
This page is information, not medical advice. Discuss any trial with your doctor.